These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30630024)

  • 1. A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis.
    Chipalkatti N; Lee N; Zancanaro P; Dumont N; Kachuk C; Rosmarin D
    J Am Acad Dermatol; 2019 Apr; 80(4):1166-1167. PubMed ID: 30630024
    [No Abstract]   [Full Text] [Related]  

  • 2. Recall dermatitis at patch test sites in an atopic dermatitis patient treated with dupilumab.
    Collantes-Rodríguez C; Jiménez-Gallo D; Ossorio-García L; Villegas-Romero I; Linares-Barrios M
    Contact Dermatitis; 2019 Jan; 80(1):69-70. PubMed ID: 30334260
    [No Abstract]   [Full Text] [Related]  

  • 3. Allergic contact dermatitis to Compositae: A possible cause of dupilumab-associated facial and neck dermatitis in atopic dermatitis patients?
    Napolitano M; Fabbrocini G; Patruno C
    Contact Dermatitis; 2021 Oct; 85(4):473-474. PubMed ID: 33988858
    [No Abstract]   [Full Text] [Related]  

  • 4. Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis.
    Stout M; Silverberg JI
    J Am Acad Dermatol; 2019 Jul; 81(1):157-162. PubMed ID: 30885752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of effect of ustekinumab in treatment of allergic contact dermatitis.
    Bangsgaard N; Zachariae C; Menné T; Skov L
    Contact Dermatitis; 2011 Oct; 65(4):227-30. PubMed ID: 21718332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus.
    Tavakolpour S
    Dermatol Ther; 2016 Sep; 29(5):299. PubMed ID: 26800435
    [No Abstract]   [Full Text] [Related]  

  • 7. Dupilumab (Dupixent) for moderate to severe atopic dermatitis.
    Med Lett Drugs Ther; 2017 Apr; 59(1519):64-66. PubMed ID: 28419072
    [No Abstract]   [Full Text] [Related]  

  • 8. [Key-studies on dupilumab].
    Velter C
    Ann Dermatol Venereol; 2018; 145(8-9):532-538. PubMed ID: 30093077
    [No Abstract]   [Full Text] [Related]  

  • 9. The beginning of biological treatment era in the atopic dermatitis management.
    D'erme AM
    Dermatol Ther; 2016 May; 29(3):208-9. PubMed ID: 26331894
    [No Abstract]   [Full Text] [Related]  

  • 10. Dupilumab for the treatment of refractory allergic contact dermatitis from rubber/latex concomitant with atopic dermatitis.
    Koh YG; Park JW; Shin SH; Kim BJ; Yoo KH
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):e640-e643. PubMed ID: 35338674
    [No Abstract]   [Full Text] [Related]  

  • 11. Dupilumab for treatment of atopic dermatitis.
    Seegräber M; Srour J; Walter A; Knop M; Wollenberg A
    Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case series of dupilumab-treated allergic contact dermatitis patients.
    Goldminz AM; Scheinman PL
    Dermatol Ther; 2018 Nov; 31(6):e12701. PubMed ID: 30246906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab for Systemic Allergy Syndrome With Dermatitis.
    Jacob SE; Sung CT; Machler BC
    Dermatitis; 2019; 30(2):164-167. PubMed ID: 30829809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart review.
    Raffi J; Suresh R; Botto N; Murase JE
    J Am Acad Dermatol; 2020 Jan; 82(1):132-138. PubMed ID: 31562940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alopecia Universalis and Atopic Dermatitis Improvement with Dupilumab: Demonstration of a Shared Pathophysiology and Clinical Efficacy.
    Dobkin H; Mullen R; Zirwas M
    Skinmed; 2019; 17(2):139-140. PubMed ID: 31145072
    [No Abstract]   [Full Text] [Related]  

  • 16. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
    Bakker DS; Ariens LFM; Giovannone B; Hijnen D; Delemarre EM; Knol E; Nierkens S; de Bruin-Weller MS; Thijs JL; Drylewicz J
    Allergy; 2020 Dec; 75(12):3287-3289. PubMed ID: 33305359
    [No Abstract]   [Full Text] [Related]  

  • 17. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patch Testing in a Patient on Dupilumab.
    Hoot JW; Douglas JD; Falo LD
    Dermatitis; 2018; 29(3):164. PubMed ID: 29570490
    [No Abstract]   [Full Text] [Related]  

  • 19. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
    Simpson EL; Bieber T; Guttman-Yassky E; Beck LA; Blauvelt A; Cork MJ; Silverberg JI; Deleuran M; Kataoka Y; Lacour JP; Kingo K; Worm M; Poulin Y; Wollenberg A; Soo Y; Graham NM; Pirozzi G; Akinlade B; Staudinger H; Mastey V; Eckert L; Gadkari A; Stahl N; Yancopoulos GD; Ardeleanu M;
    N Engl J Med; 2016 Dec; 375(24):2335-2348. PubMed ID: 27690741
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.